TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04578262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epley Manoeuvre
Description: This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Manoeuvre
Description: The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
Study: NCT01914796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06412562
Description: Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06412562
Description: It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
Study: NCT03176680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid therapy optimization
Description: colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
Study: NCT01306162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg as single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
Study: NCT04582409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSY244
Description: HSY244 concentrate solution for injection via intravenous infusion
Study: NCT01306162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate plus dronedarone
Description: dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
Study: NCT02626715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced-Intensity Conditioning Regimen
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myeloablative Conditioning Regimen
Description: Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
Study: NCT00319878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Dose of 5 mg/kg divided as a twice daily oral dose
Study: NCT00761332

Intervention type: DRUG
Intervention: teriparatide
Description: treatment will be prescribed according to usual standard of care

Intervention type: DRUG
Intervention: antiresorptives
Description: treatment will be prescribed according to usual standard of care
Study: NCT02552706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose solution
Description: Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
Study: NCT03436797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
Study: NCT04196517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Tool, PALS
Description: The Patient Activated Learning System is a free, health education platform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebMD
Description: WebMD is a widely used educational platform for health information.
Study: NCT04582409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concentrate solution for injection via intravenous infusion
Study: NCT00966082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation
Description: Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic band ligation+Propranolol
Description: Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
Study: NCT02305667

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh
Description: double lumen tube intubation using the Macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope®
Description: double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq®
Description: double lumen tube intubation using the Airtraq® videolaryngoscope.
Study: NCT00690768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy 3 weeks after baseline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy 3 weeks after baseline
Study: NCT03230968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integral Action Program for Respiration
Study: NCT02868307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Answering questionnaire
Study: NCT01074307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Bisoprolol
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Bisoprolol
Description: Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
Study: NCT02037373

Intervention type: BIOLOGICAL
Intervention: Octaplas™
Description: Octaplas™ infusion solution for IV administration as prescribed by the treating physician.

Intervention type: BIOLOGICAL
Intervention: Plasma
Description: Plasma as prescribed by the treating physician.
Study: NCT01120600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: One 50 mg tablet once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Odanacatib
Description: One 50 mg tablet once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5600 IU of open-label Vitamin D3 once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 5600 IU of open-label Vitamin D3 once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
Study: NCT02964065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live-Attenuated influenza Vaccine(LAIV)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03134417

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and magnesium
Description: Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily vitamin D supplements are given to participants daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo are given to participants daily for 12 weeks.
Study: NCT02123069

Intervention type: DEVICE
Intervention: Brachial artery catheter
Description: A catheter will be placed in the brachial artery by a physician on the study day.

Intervention type: DEVICE
Intervention: Brachial artery catheter
Description: A catheter will be placed in the brachial artery by a physician on the study day.

Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Nitroprusside
Description: Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Nitroprusside
Description: Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.

Intervention type: DRUG
Intervention: Nitroprusside and phenylephrine
Description: A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.

Intervention type: DRUG
Intervention: Nitroprusside and phenylephrine
Description: A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
Study: NCT04157270

Intervention type: DEVICE
Intervention: Penumbra System
Description: Penumbra System
Study: NCT02197169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intratumoral injection of DNX-2401
Description: In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intratumoral injection of DNX-2401
Description: In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-gamma
Description: In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
Study: NCT03152227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACGG
Description: 50 high-producing chicks to households along with provision of technical input on production

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACGG
Description: 50 high-producing chicks to households along with provision of technical input on production

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC
Description: Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
Study: NCT02305667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision™
Description: double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
Study: NCT01516710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open liver resection
Description: Patients will be operated with open liver resection for colorectal metastasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic liver resection
Description: Patients will be operated with laparoscopic liver resection
Study: NCT04729218

Intervention type: BEHAVIORAL
Intervention: movement imagery ability
Description: Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery

Intervention type: BEHAVIORAL
Intervention: movement imagery ability
Description: Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
Study: NCT02498899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants watch a video lasting about 4 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants watch a video lasting about 4 minutes.
Study: NCT01318941

Intervention type: DRUG
Intervention: Ranibizumab

Intervention type: OTHER
Intervention: Ranibizumab
Study: NCT02686489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated humidification
Description: Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool bland aerosol
Description: Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
Study: NCT03875430

Intervention type: DIETARY_SUPPLEMENT
Intervention: Humulus lupulus L
Description: Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause

Intervention type: DIETARY_SUPPLEMENT
Intervention: Humulus lupulus L
Description: Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
Study: NCT03402178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2082
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
Study: NCT01408576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
Study: NCT03820973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT for Anxiety
Description: All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
Study: NCT02872337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Physical Therapy Session
Description: This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group Preoperative Education Session (per the standard of care)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Preoperative Education Session (per the standard of care)
Study: NCT05143086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash 100% Nano-F
Description: Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash 50% Nano-F
Description: Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash standard
Description: Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use 10 ml of mouthwash without fluoride
Study: NCT00078819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to etanercept administered by subcutaneous injection once a week